no weight loss tirzepatide ✨ Before & After Transformation — 3 Months on ✨ There is better feeling than when a patient sends their own before & after because they are truly proud of Tirzepatide, without the needle.⁠ ⁠

Herein, we report the first differences in signaling between the two variants

Expert Consensus: American College of Physicians: GLP-1 receptor agonists should be considered for patients with obesity who have not achieved weight loss goals with lifestyle modifications. Endocrine Society: Semaglutide and tirzepatide represent significant advances in obesity pharmacotherapy and should be considered first-line options. Obesity Medicine Association: The dramatic efficacy of GLP-1 and dual agonist medications has fundamentally changed the treatment landscape for obesity. Real-World Effectiveness: Studies of patients using these medications outside clinical trials show: GLP-1s: Similar to clinical trial results (confirming real-world effectiveness) Older medications: Often less effective in real-world than trials (adherence issues) Patient satisfaction: Highest with GLP-1s Bottom Line: Which Works Best

Consulting with Healthcare Providers Its crucial to consult with your Elase provider to determine the most appropriate treatment

These peptides improve insulin sensitivity, reduce HbA1c levels, and support weight loss, thereby enhancing metabolic control